A Study of Mircera for the Treatment of Anemia in Dialysis Patients
| Status: | Completed |
|---|---|
| Conditions: | Anemia |
| Therapuetic Areas: | Hematology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 8/3/2016 |
| Start Date: | February 2004 |
| End Date: | June 2006 |
A Randomized, Open-label Study of the Effect of Intravenous Mircera on Hemoglobin Level/Correction in Dialysis Patients With Chronic Kidney Disease
This study will assess the efficacy and safety of Mircera given intravenously in the
treatment of renal anemia in chronic kidney disease patients on dialysis who are not
currently receiving epoetin or any other erythropoietic substance. The anticipated time on
study treatment is 1-2 years and the target sample size is 100-500 individuals.
treatment of renal anemia in chronic kidney disease patients on dialysis who are not
currently receiving epoetin or any other erythropoietic substance. The anticipated time on
study treatment is 1-2 years and the target sample size is 100-500 individuals.
Inclusion Criteria:
- adult patients >=18 years of age;
- chronic renal anemia;
- dialysis therapy for at least 2 weeks before screening.
Exclusion Criteria:
- women who are pregnant, breastfeeding or using unreliable birth control methods;
- administration of any investigational drug within 4 weeks before screening.
We found this trial at
15
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials